9.13
前日終値:
$9.09
開ける:
$9.04
24時間の取引高:
553.85K
Relative Volume:
0.55
時価総額:
$460.05M
収益:
$89.04M
当期純損益:
$-241.08M
株価収益率:
-1.7357
EPS:
-5.26
ネットキャッシュフロー:
$-194.72M
1週間 パフォーマンス:
+5.06%
1か月 パフォーマンス:
+6.66%
6か月 パフォーマンス:
+15.86%
1年 パフォーマンス:
-33.06%
Regenxbio Inc Stock (RGNX) Company Profile
RGNX を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
RGNX
Regenxbio Inc
|
9.13 | 431.83M | 89.04M | -241.08M | -194.72M | -5.26 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-02-11 | ダウングレード | Goldman | Buy → Neutral |
2025-02-07 | 再開されました | Raymond James | Outperform |
2024-11-15 | 再開されました | Morgan Stanley | Overweight |
2024-10-10 | 再開されました | Raymond James | Outperform |
2024-06-07 | 開始されました | Goldman | Buy |
2024-03-11 | 開始されました | H.C. Wainwright | Buy |
2024-03-08 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
2024-03-06 | アップグレード | Leerink Partners | Market Perform → Outperform |
2024-02-21 | 再開されました | Raymond James | Outperform |
2023-11-01 | 開始されました | Stifel | Buy |
2023-06-02 | 開始されました | Robert W. Baird | Outperform |
2022-06-23 | 開始されました | Berenberg | Buy |
2021-12-15 | 開始されました | Wedbush | Neutral |
2021-10-19 | 再開されました | Morgan Stanley | Overweight |
2021-01-06 | アップグレード | Raymond James | Outperform → Strong Buy |
2020-12-16 | 開始されました | UBS | Buy |
2020-06-25 | 再開されました | BofA/Merrill | Buy |
2020-05-13 | 開始されました | RBC Capital Mkts | Sector Perform |
2019-08-20 | アップグレード | SVB Leerink | Underperform → Mkt Perform |
2019-06-18 | 繰り返されました | Chardan Capital Markets | Buy |
2019-06-14 | 再開されました | Raymond James | Outperform |
2019-06-05 | 繰り返されました | Chardan Capital Markets | Buy |
2019-02-25 | アップグレード | Evercore ISI | In-line → Outperform |
2019-02-05 | アップグレード | Raymond James | Outperform → Strong Buy |
2018-12-17 | 繰り返されました | Chardan Capital Markets | Buy |
2018-11-08 | 繰り返されました | BofA/Merrill | Neutral |
2018-08-08 | 繰り返されました | Chardan Capital Markets | Buy |
2018-07-23 | ダウングレード | BofA/Merrill | Buy → Neutral |
2018-07-10 | 繰り返されました | Chardan Capital Markets | Buy |
2018-05-09 | 繰り返されました | Barclays | Overweight |
2018-04-09 | 繰り返されました | Chardan Capital Markets | Buy |
2018-03-12 | ダウングレード | Evercore ISI | Outperform → In-line |
2018-02-13 | 開始されました | Mizuho | Neutral |
2017-11-09 | 再開されました | Morgan Stanley | Overweight |
すべてを表示
Regenxbio Inc (RGNX) 最新ニュース
What institutions are buying REGENXBIO Inc. stock nowTriple returns potential - jammulinksnews.com
REGENXBIO Inc. (RGNX): A Bull Case Theory - Insider Monkey
What analysts say about REGENXBIO Inc. stockStrong return on investment - Autocar Professional
The Duchenne Gene Therapies Lining Up To Take Elevidys’ Place - insights.citeline.com
What drives REGENXBIO Inc. stock priceOverwhelming profit margins - Autocar Professional
REGENXBIO Inc. Stock Analysis and ForecastExplosive trading opportunities - jammulinksnews.com
Is REGENXBIO Inc. a good long term investmentConsistently outstanding ROI - jammulinksnews.com
REGENXBIO Inc. (NASDAQ:RGNX) is largely controlled by institutional shareholders who own 67% of the company - Yahoo Finance
(RGNX) Technical Pivots with Risk Controls - news.stocktradersdaily.com
REGENXBIO announces royalty monetization agreement for up to $250M - MSN
REGENXBIO’s gene therapy with CT domain shows improved muscle function in study By Investing.com - Investing.com South Africa
REGENXBIO’s gene therapy with CT domain shows improved muscle function in study - Investing.com
REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy - WV News
Diabetic Retinopathy Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | | Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics - Barchart.com
RBC Capital Remains a Buy on RegenXBio (RGNX) - The Globe and Mail
RBC Capital Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $21 - 富途牛牛
Regenxbio (RGNX) Maintains Strong Outlook Amid Competitor Safety Concerns | RGNX Stock News - GuruFocus
REGENXBIO (RGNX) Prepares for Potential $4M Warrant Cash Influx - GuruFocus
Regenxbio (RGNX) Proposes Sale of Over 268,000 Shares | RGNX Stock News - GuruFocus
Regenxbio (RGNX) Maintains Buy Rating with $52 Price Target | RGNX Stock News - GuruFocus
A Glimpse Into The Expert Outlook On Regenxbio Through 8 Analysts - Benzinga
Promising RGX-202 Trial Results Justify Buy Rating for RegenXBio Amid Market Skepticism - TipRanks
REGENXBIO updates Phase 1/2 data for Duchenne candidate - MSN
Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome - Seeking Alpha
H.C. WAINWRIGHT MAINTAINS BUY RATING ON REGENXBIO STOCK AFTER POSITIVE TRIAL DATA - Investing.com Nigeria
Duchenne gene therapy interim trial outcomes "striking" - MarketScreener
Otsuka tops Vera with kidney drug data; Regenxbio sinks on Duchenne update - BioPharma Dive
RegeNXBio shares fall, despite positive new data on RGX-202 - The Pharma Letter
REGENXBIO reports progress in Duchenne treatment trial By Investing.com - Investing.com South Africa
Regenxbio’s Duchenne gene therapy data positive as shares falter - BioWorld MedTech
New Regenxbio DMD Data Support Gene Therapy Accelerated Approval - insights.citeline.com
Stifel reiterates Buy rating on Regenxbio stock after trial data By Investing.com - Investing.com Nigeria
Stifel reiterates Buy rating on Regenxbio stock after trial data - Investing.com Australia
REGENXBIO reports new positive functional data from phase I/II AFFINITY Duchenne® trial of RGX-202 - Pipelinereview
Regenxbio’s Gene Therapy Helps Kids with Deadly Muscle Disease - Bloomberg
Regenxbio Inc (RGNX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):